1-4 of 4
Wayne M. Rothbaum
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 1b-2 Study of KRT-232, a First-in-Class, Oral, Small Molecule Inhibitor of Murine Double Minute 2 (MDM2), in Combination with Acalabrutinib for the Treatment of Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Peter Hillmen, MBChB, PhD FRCP, FRCPath, Hope Qamoos, CNP, Anne Uyei, MD, Wayne M. Rothbaum, Wojciech Jurczak, MD PhD, Catherine Thieblemont, MD PhD, John C. Byrd, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 23–24.
https://doi.org/10.1182/blood-2020-134901
Published: 2020
Journal Articles

An Open-Label, Phase 2 Study of KRT-232, a First-in-Class, Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients with Myelofibrosis (MF) Who Have Previously Received Treatment with a JAK Inhibitor

Regina Garcia-Delgado, MD, Donal P. McLornan, MB, BCh (Hons), MRCP, PhD FRCPath, László Rejtő, Eric Jourdan, MD, Haifa Kathrin Al-Ali, MD, Andrzej Pluta, MD, Marek Hus, MD PhD, Joanne Ewing, PhDBMBS BSc FRPATH, Irum Khan, MD, Holger Hebart, Philipp J. Jost, MD, Sebastian Grosicki, MD PhD, Wayne M. Rothbaum, Jesse McGreivy, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2945.
https://doi.org/10.1182/blood-2019-123836
Published: 2019
Journal Articles

A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared with Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera

Jason Gotlib, MD MS, Nashat Gabrail, MD, Casey L. O'Connell, MD, Regina Garcia-Delgado, MD, Timothy Sbardellati, Wayne M. Rothbaum, Jesse McGreivy, Claire N Harrison, Professor, Jean-Jacques Kiladjian, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4168.
https://doi.org/10.1182/blood-2019-123546
Published: 2019
Journal Articles

Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results from the Phase 1/2 ACE-CL-001 Study

John C. Byrd, MD, William G Wierda, MD PhD, Anna Schuh, MD PhD, Stephen Devereux, FRCP, FRCPath, PhD, Jorge M. Chaves, MD, Jennifer R. Brown, MD PhD, Peter Hillmen, MBChB, PhD, Peter Martin, MD, Farrukh T. Awan, MD MS, Deborah M. Stephens, DO, Paolo Ghia, MD PhD, Jacqueline C. Barrientos, MD, John M. Pagel, MD PhD, Jennifer A. Woyach, MD, Prista Charuworn, MD, Ahmed Hamdy, MD, Raquel Izumi, PhD, Priti Patel, MD, Wayne M. Rothbaum, Min Hui Wang, PhD, Richard R. Furman, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 498.
https://doi.org/10.1182/blood.V130.Suppl_1.498.498
Published: 2017